425: Boston Scientific to Acquire Penumbra for $15 Billion

Boston Scientific Corporation announced an agreement to acquire Penumbra, a medical technology company specializing in neurovascular and mechanical thrombectomy, for $15 billion in cash and stock.

Summary

• Boston Scientific has entered into an agreement to acquire Penumbra for a total consideration of $15 billion, or $374 per Penumbra common share.
• The transaction will be funded with approximately $11 billion in cash and $4 billion in Boston Scientific stock, representing a 73% cash, 27% stock mix.
• Penumbra's Q4 2025 revenue growth is expected to be in the range of 21.4% to 22%, leading to a full-year preliminary revenue of $1.4 billion, representing growth of approximately 17.3% to 17.5%.
• The acquisition is expected to be slightly dilutive to Boston Scientific's adjusted operating margin and adjusted EPS ($0.06 to $0.08) in the first full year post-close.
• The transaction is anticipated to be neutral to slightly accretive to adjusted operating margin and slightly accretive to adjusted EPS in year two, becoming increasingly accretive thereafter.
• Over $200 million in operating income impact from revenue synergies and cost efficiencies are expected to be fully realized by year three.
• The acquisition is expected to close in 2026, with the second half being more likely, subject to customary closing conditions.
• Penumbra will largely operate as a standalone organization within Boston Scientific's cardiovascular group, leveraging Boston Scientific's global capabilities and footprint.

Sentiment

Score: 8

Explanation: The filing announces a major strategic acquisition with strong growth potential, entry into new high-growth markets, and expected long-term financial accretion, despite initial dilution. Management expresses high confidence and cultural alignment, positioning the combined entity for accelerated growth and market leadership.

Positives

• The acquisition provides Boston Scientific entry into high-growth segments, including mechanical thrombectomy and neurovascular, where it currently lacks offerings.
• Penumbra brings a highly differentiated portfolio of novel technologies and a strong track record of innovation, execution, and growth.
• Boston Scientific's broad capabilities, including supply chain expertise and a significant global commercial footprint, will enable wider access to Penumbra technologies.
• The deal is expected to be growth accretive to Boston Scientific, supporting its long-range plan goals of 10%+ compounded annual growth for adjusted operating margin and leveraged double-digit EPS over 2026-2028.
• Strong cultural alignment between the two companies, focusing on innovation, clinical evidence, and patient care, is expected to accelerate growth.
• Adam Elsesser, Penumbra's Chairman and CEO, will join Boston Scientific's Board of Directors, underscoring commitment to the combined companies' success.
• The deal structure maintains flexibility for Boston Scientific for additional potential tuck-in M&A or share repurchases while committing to credit ratings.
• Boston Scientific expects to achieve high single-digit Return on Invested Capital (ROIC) by year five.

Negatives

• The transaction is expected to be slightly dilutive to Boston Scientific's adjusted operating margin in the first full year post-close.
• Adjusted EPS is expected to be dilutive by $0.06 to $0.08 in the first full year post-close.

Risks

• The acquisition is subject to customary closing conditions, including regulatory approvals, which could impact the timing of the close.
• Potential challenges in integrating Penumbra's operations and maintaining its innovation cadence within a larger corporate structure, despite plans for standalone operation.
• The competitive landscape in mechanical thrombectomy is intense, with many competitors.

Future Outlook

Boston Scientific expects the acquisition to significantly enhance its long-range plan goals for 2026-2028, including achieving 10%+ compounded annual growth for adjusted operating margin, 150 basis points of margin expansion, and leveraged double-digit EPS growth. Penumbra's neurovascular market is anticipated to evolve with new products, particularly in embolizing the middle meningeal artery, offering significant growth opportunities over the next two to three years. The combined entity aims to treat more patients globally with Penumbra's innovative technologies.

Management Comments

• "We're highly confident this deal is both strategically and financially attractive to Boston Scientific and delivers significant value to patients, customers, and our shareholders." Michael F. Mahoney, Chairman and CEO, Boston Scientific
• "Penumbra is a great company, a highly differentiated portfolio of novel technologies that operate in high-growth segments where Boston Scientific lacks offerings, including mechanical thrombectomy and neurovascular." Michael F. Mahoney, Chairman and CEO, Boston Scientific
• "We expect our Q4 '25 revenue growth to be in the range of 21.4% to 22%, resulting in full-year preliminary revenue of $1.4 billion, representing growth in the range of approximately 17.3% to 17.5%." Adam Elsesser, Chairman and CEO, Penumbra
• "This is a highly strategic acquisition and the deal structure enables us to maintain flexibility for additional potential tuck-in M&A or share repurchase while maintaining a firm commitment to our credit ratings." Jonathan Monson, Executive Vice President and CFO, Boston Scientific
• "This is about us getting stronger when we're very strong." Michael F. Mahoney, Chairman and CEO, Boston Scientific
• "We're very confident in our ability to deliver that double-digit EPS growth over the three years. And it'd be very disappointing. So, that's what we're going to do." Michael F. Mahoney, Chairman and CEO, Boston Scientific

Industry Context

This acquisition positions Boston Scientific to re-enter and become a scaled, market-leading player in the high-growth neurovascular and mechanical thrombectomy segments, areas where it previously lacked offerings. The move aligns with the broader medical device industry trend towards minimally invasive solutions for complex diseases and leveraging global commercial footprints to expand market access for innovative technologies. Penumbra's strong pipeline and market presence in these areas complement Boston Scientific's existing cardiovascular portfolio, particularly in vascular surgery call points where Boston Scientific has been underpenetrated.

Management Changes

Corporate Governance

Legal Proceedings

• The transaction is subject to a regulatory process, which Boston Scientific will not comment on further at this point.

Stakeholder Impact

• **Shareholders (Boston Scientific):** Expected long-term value creation through entry into high-growth markets and anticipated financial accretion, despite initial short-term dilution to EPS and operating margin.
• **Shareholders (Penumbra):** Receive significant value at $374 per share in cash and stock, with Penumbra's CEO electing to receive Boston Scientific stock.
• **Patients and Customers:** Will benefit from expanded access to highly differentiated, minimally invasive technologies globally, addressing significant clinical challenges.
• **Employees (Penumbra):** Will be welcomed into Boston Scientific, with plans for Penumbra to operate largely standalone to maintain its innovation culture, offering new growth and development opportunities within a larger global company.
• **Employees (Boston Scientific):** The acquisition expands the company's market reach and product portfolio, potentially creating new collaboration opportunities and strengthening its overall market position.

Next Steps

• Boston Scientific will file a registration statement on Form S-4 containing a proxy statement of Penumbra and a prospectus of Boston Scientific with the SEC.
• The acquisition is subject to customary closing conditions and regulatory approval processes.
• Penumbra will operate essentially as a standalone organization within Boston Scientific's cardiovascular group post-close.
• Adam Elsesser will join Boston Scientific's Board of Directors upon the closing of the transaction.

Key Dates

Recommendation

The acquisition of Penumbra is a highly strategic and transformative move for Boston Scientific, providing immediate entry into the high-growth neurovascular and mechanical thrombectomy markets with a leading, innovative portfolio. While there is an expected short-term dilution to EPS and operating margin, the long-term financial accretion, significant revenue synergies, and strong cultural alignment position Boston Scientific for accelerated growth and margin expansion, reinforcing its long-range plan goals. The deal strengthens Boston Scientific's overall market position, innovation pipeline, and global reach, making it a compelling investment for long-term growth.

Keywords

Acquisition, Merger, Medical Devices, Neurovascular, Mechanical Thrombectomy, Peripheral Interventions, Cardiovascular, SEC Filing, Financial Results, Growth Strategy